Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Hospital Progress|February 10, 1981
Trusteeship: shared mission for religious and laityW L Longo
The American Journal of Medicine|December 1, 1986
Role of the spleen in the transdiaphragmatic spread of Hodgkin's diseaseJ L Mann, G R Hafez, W L Longo
Cancer|July 15, 1990
Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposideR D McCroskey, D F Mosher, C D Spencer, et al.
Cancer Research|November 15, 1988
Phase I trial of lonidamine with whole body hyperthermia in advanced cancerH I Robins, W L Longo, R K Lagoni, et al.
Bone Marrow Transplantation|July 22, 1999
Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicityS Mineishi, W L Longo, M E Atkinson, et al.
Bone Marrow Transplantation|January 6, 2004
A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepaA G McCoy, E P Smith, M E Atkinson, et al.
International Journal of Radiation Oncology, Biology, Physics|August 1, 1988
A pilot study of whole body hyperthermia and local irradiation for advanced non-small cell lung cancer confined to the thoraxH I Robins, W L Longo, R A Steeves, et al.
Leukemia & Lymphoma|May 30, 2001
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemiaB Vidarsson, R Abonour, E C Williams, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 1990
Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigationsH I Robins, W L Longo, R A Steeves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology NetworkB S Kahl, W L Longo, J C Eickhoff, et al.
Pageof 2